

## <sup>177</sup>Lu-Dotatate Therapy

### PREPARATION

---

- The patient must schedule an appointment with one of our nuclear doctors. In this consultation, the doctor will evaluate the patient's clinical condition and recent exams (scintigraphy with somatostatin analogue, blood counts, urea, creatinine, PETCT, magnetic resonance imaging, computed tomography, anatomopathological and immunohistochemical report of the biopsied lesion), in addition to advising on the therapy, including its benefits and possible complications. At this point, the patient must sign the informed consent form.
- Fasting from 04 to 06 hours and good hydration is recommended.
- Withhold therapy with short-acting somatostatin analogues (Octreotide/Sandostatin and Pasireotide/Signifor) for 48 hours and long-acting (Lanreotide/Somatuline) for one month.
- This therapy is not indicated for pregnant or breastfeeding women.

### HOW IS THERAPY PERFORMED?

---

After filling out the registration form at the reception, the patient will be sent to the bedrest room in the clinic or to a hospital room (in general, for a 12-hour hospitalization).

In the bedrest room or hospital room, a peripheral vein of each upper limb will be punctured and maintained with saline.

A nephroprotective amino acid solution will be infused over 4 hours into one of the punctured veins.

In another vein, anti-emetics will be infused for 15 minutes. At the end, the radioactive agent will be infused into this same vein, 30 minutes after the start of the infusion of amino acids. The infusion of the radioactive agent should be slow, lasting around 30 minutes.

After the end of the infusion of the radioactive agent, the venous access of this limb will be removed and only the venous access where the amino acids are being infused will be maintained.

Once the amino acid infusion is completed, the venous access will be removed and the patient can be discharged from the hospital after clinical evaluation, with instructions to return in 24 to 48 hours for image acquisition.

Radioprotection instructions and the requests for further blood tests will be provided for the patient. Somatostatin will be resumed after treatment with Lutetium-Dotatate.